Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novel US FDA Approvals Could Rebound In 2017: 40+ Candidates Already Under Review

Feb 23 2017

• By Bridget Silverman

Binocular viewer_1200X675

Related Content

What Goes Up … US FDA Expects 2016 NME Approval Total To Come Down

Nov 08 2016

Novel Approvals Were Fewer But Faster At US FDA In 2016

Jan 02 2017

Time For Big Pharma To Take Back Orphan Drugs

Feb 15 2017

US FDA Approval Of Valeant’s Siliq Comes With REMS, Boxed Warning

Feb 16 2017

Related Companies

Biogen, Inc.

Ionis Pharmaceuticals, Inc.

Synergy Pharmaceuticals, Inc.

Amgen, Inc.

Marathon Pharmaceuticals LLC

Bausch Health Companies Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Neurocrine Biosciences, Inc.

Pfizer Inc.

Merck KGaA

AstraZeneca PLC

Genentech, Inc.

BioMarin Pharmaceutical Inc.

Mitsubishi Tanabe Pharma Corporation

Teva Pharmaceutical Industries Ltd.

Johnson & Johnson

GSK plc

Eli Lilly and Company

Incyte Corporation

Additional Topics

United States Approvals Review Pathway Regulation BioPharmaceutical

More from Approvals

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window